The estimated Net Worth of Robert E. Gagnon is at least $5.12 Million dollars as of 17 June 2024. Mr. Gagnon owns over 414 units of Verastem Inc stock worth over $98,868 and over the last 14 years he sold VSTM stock worth over $3,427,082. In addition, he makes $1,597,300 as Chief Financial Officer and Chief Business Officer at Verastem Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Gagnon VSTM stock SEC Form 4 insiders trading
Robert has made over 41 trades of the Verastem Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he sold 414 units of VSTM stock worth $1,408 on 17 June 2024.
The largest trade he's ever made was selling 169,200 units of Verastem Inc stock on 9 July 2018 worth over $889,992. On average, Robert trades about 7,589 units every 62 days since 2010. As of 17 June 2024 he still owns at least 35,310 units of Verastem Inc stock.
You can see the complete history of Mr. Gagnon stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Gagnon biography
Robert E. Gagnon serves as Chief Financial Officer, Chief Business Officer of the Company. Prior to joining us, Mr. Gagnon served as the Chief Financial Officer for Harvard Bioscience, Inc. from November 2013 to August 2018. From 2012 through 2013, Mr. Gagnon served as the Executive Vice President, Chief Financial Officer and Treasurer at Clean Harbors, Inc. Mr. Gagnon’s prior experience includes serving as Chief Accounting Officer and Controller at Biogen Idec, Inc., as well as a variety of senior positions at Deloitte & Touche, LLP, and PriceWaterhouseCoopers, LLP. Mr. Gagnon holds an M.B.A from the MIT Sloan School of Management and a Bachelor of Arts degree in accounting from Bentley College.
What is the salary of Robert Gagnon?
As the Chief Financial Officer and Chief Business Officer of Verastem Inc, the total compensation of Robert Gagnon at Verastem Inc is $1,597,300. There are 2 executives at Verastem Inc getting paid more, with Brian Stuglik having the highest compensation of $1,917,190.
How old is Robert Gagnon?
Robert Gagnon is 45, he's been the Chief Financial Officer and Chief Business Officer of Verastem Inc since 2020. There are 14 older and 1 younger executives at Verastem Inc. The oldest executive at Verastem Inc is Timothy Barberich, 72, who is the Independent Director.
What's Robert Gagnon's mailing address?
Robert's mailing address filed with the SEC is C/O VERASTEM, INC.,, 117 KENDRICK ST., SUITE 500, NEEDHAM, MA, 02494.
Insiders trading at Verastem Inc
Over the last 13 years, insiders at Verastem Inc have traded over $5,883,823 worth of Verastem Inc stock and bought 3,873,819 units worth $28,318,633 . The most active insiders traders include Capital Management, L.P.Ra ..., Christoph H Westphal, and Ansbert Gadicke. On average, Verastem Inc executives and independent directors trade stock every 28 days with the average trade being worth of $112,479. The most recent stock trade was executed by Dan Paterson on 5 August 2024, trading 3,245 units of VSTM stock currently worth $7,009.
What does Verastem Inc do?
verastem, inc. (nasdaq: vstm) is a biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells. cancer stem cells are an underlying cause of tumor recurrence and metastasis. verastem is translating breakthrough discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer. for more information, please visit www.versatem.com
What does Verastem Inc's logo look like?
Complete history of Mr. Gagnon stock trades at Biogen Inc, Harvard Bioscience, Verastem Inc, and Clean Harbors
Verastem Inc executives and stock owners
Verastem Inc executives and other stock owners filed with the SEC include:
-
Brian Stuglik,
Chief Executive Officer, Director -
Daniel Paterson,
President, Chief Operating Officer -
Robert Gagnon,
Chief Financial Officer, Chief Business Officer -
Brian M. Stuglik BPHARM, R.Ph., RPh,
CEO & Director -
Brian Stuglik R.Ph., RPh,
CEO & Director -
Daniel W. Paterson,
COO & Pres -
Robert E. Gagnon,
Chief Bus. & Financial Officer -
Michael Kauffman,
Lead Independent Director -
Timothy Barberich,
Independent Director -
Eric Rowinsky,
Independent Director -
Alison Lawton,
Independent Director -
Bruce Wendel,
Independent Director -
Gina Consylman,
Independent Director -
John Doyle,
Investor Relations -
Dr. Michelle Dipp M.D., Ph.D.,
Co-Founder -
Sean C. Flynn,
VP, Gen. Counsel & Sec. -
Erin S. Cox,
Sr. Director of Investor Relations & Corp. Communications -
Dr. Jonathan Pachter Ph.D.,
Chief Scientific Officer -
Dr. Michelle Dipp,
Co-Founder -
Dr. Piyush B. Gupta Ph.D.,
Co-Founder -
Dr. Robert A. Weinberg,
nder & Former Chair of Scientific Advisory Board -
Richard H. Aldrich M.B.A., Mba,
Founder and Consultant -
S. Louise Phanstiel,
Director -
Joseph Chiapponi,
Vice President of Finance -
John B Green,
Chief Financial Officer -
Monica Singh,
General Counsel -
Henri A Termeer,
Director -
Stephen A Sherwin,
Director -
Christoph H Westphal,
Executive Chairman -
Paul A Friedman,
Director -
Karin Anna Tollefson,
Director -
Steven H. Bloom,
Chief Strategy Officer -
Julie B Feder,
Chief Financial Officer -
Robert Forrester,
President and CEO -
Ngoc Diep T. Md, Ph D Le,
Chief Medical Officer -
Joseph M Lobacki,
Executive VP & CCO -
Gregory Berk,
Chief Medical Officer -
Capital Investments L.P.Rid...,
-
Capital Management, L.P.Ra ...,
-
John Johnson,
Director -
Management Co. Llc Deer,
Director -
Iii Lp Chp,
10% owner -
John K Clarke,
Director -
Joanna Horobin,
Chief Medical Officer -
Jonathan Pachter,
VP, Head of Research -
Fund, L.P. Longwood,
10% owner -
Venture Partners Vii L.P.Be...,
-
Stephen Kraus,
Director -
Ansbert Gadicke,
Director -
Bioventures V Llcmpm Bioven...,
-
Piyush Gupta,
10% owner -
Iii Lpchp Iii Management, L...,
-
Daniel Calkins,
Chief Financial Officer -
Frank Neumann,
Chief Medical Officer -
Paul A. Bunn,
Director -
Lesley Kim Solomon,
Director -
Michelle Robertson,
Director -
Anil Kapur,
Director -
Dan Paterson,
President and CEO